What the Sequence of Constraints Means
This series has examined innovative start-ups in the EU and the US not as a contest of ideas, but as firms moving through increasingly demanding forms of growth. The final question is what the evidence justifies saying about the companies that reach advanced scale and the environments around them. The answer is that scale belongs to firms that can repeatedly convert one advantage into the next: invention into commercial evidence, evidence into deep financing, financing into market reach, reach into an organisation, and organisational capability into wider ecosystem effects. None of those conversions is guaranteed, and no single one explains the EU–US gap by itself.
The Firms That Reach Scale Solve a Moving Constraint
A start-up can be innovative without being ready to scale. In the OECD comparison, an innovative start-up is identified by patenting or venture-capital backing. A growth-oriented firm has raised at least USD 50 million without reaching the higher valuation category. A rising superstar has reached a valuation of at least USD 1 billion, privately or through an initial public offering. These markers are useful because they separate a broad pool of firms with signals of promise from progressively rarer outcomes that require greater financing, market confidence, and organisational capacity.
The categories also prevent an overly simple answer to the question “which start-ups win?” The data assign each firm to its highest eventual observed outcome; they do not follow every company through a complete, causal lifecycle. A firm classified as a rising superstar may have passed through intermediate milestones, but the study does not establish that every company follows the same route or that firms outside the highest category failed for the same reason. The most defensible answer is therefore not a founder profile or a technology checklist. It is a capability claim: firms reach advanced scale when they can overcome several linked constraints at successive points in their growth.
The distribution shows why the claim matters. The EU and US both produce large populations of innovative start-ups, but the US has many more firms in the growth-oriented and rising-superstar categories relative to the wider start-up population. In the broader comparison, innovative firms account for roughly similar shares of EU and US start-ups, while the shares reaching the funding and valuation thresholds are higher in the US. EU rising superstars also tend to scale later. The difference is therefore concentrated in the passage from promise to advanced growth, not in the mere existence of entrepreneurial activity.
The first constraint is translation. A technical discovery becomes economically consequential only when a firm can decide how to protect it, commercialise it, and reach customers. The patent evidence makes the distinction visible. EU scale-ups are less likely than US peers to hold patents, yet among firms that do patent, their recorded invention stocks are comparable or higher on average. EU patenting scale-ups take longer after first filing to reach the scaling milestone; the reported adjusted association is approximately 1.494 additional years for EU firms after accounting for sector, founding cohort, and citation-weighted patent stock. That result is consistent with frictions in formalisation and commercialisation, but it does not identify one regulatory cause or show that firms that do not patent lack valuable knowledge.
The second constraint is capital depth. Early funding paths for EU and US rising superstars are broadly similar in the first years, and growth-oriented firms show less pronounced regional divergence. The sharper difference appears later, in the upper tail of financing. US average funding for rising superstars accelerates as firms approach advanced scale, while EU mean funding grows more gradually; medians are more similar. A small group of US firms can therefore mobilise exceptionally large late-stage rounds, even though the typical firm’s earlier path may not look radically different. The relevant capability is not simply producing seed capital. It is coordinating enough risk-tolerant capital when expansion becomes expensive and the outcome remains uncertain.
The third constraint is reach. Capital and a protected invention give a start-up options, not a market. It must obtain customers, distribution, complementary technology, specialised employees, and operating relationships. Acquisitions can compress that work by giving a scale-up access to a target’s capabilities or geography. They are particularly associated with rising superstars and are prominent in ICT, where network effects and high fixed costs can make speed valuable. But acquisition is not a magic shortcut. The firm has to integrate people and systems, retain the capability it bought, and ensure that consolidation does not undermine competition.
The fourth constraint is organisation. As a start-up grows, the founding team is asked to coordinate more financing, employees, products, markets, and governance than the early venture required. Serial founders and advanced education are associated with scaling, but the evidence does not turn those characteristics into deterministic credentials. External executives, especially CFOs, are associated with earlier scaling in the relevant models because financial governance, investor relations, and capital mobilisation become more important. An external CEO has a more ambiguous signal: replacement may represent professionalisation in one firm and a response to organisational strain in another.
The fifth constraint is connection. A firm’s ability to use capital, talent, research, and market access depends partly on the ecosystem in which those resources meet. The EU–US comparison shows denser and more concentrated entrepreneurial activity in US Functional Urban Areas.